Anticancer strategies based on the metabolic profile of tumor cells: therapeutic targeting of the Warburg effect

被引:86
作者
Chen, Xi-sha [1 ]
Li, Lan-ya [1 ]
Guan, Yi-di [1 ]
Yang, Jin-ming [2 ,3 ]
Cheng, Yan [1 ]
机构
[1] Cent S Univ, Sch Pharmaceut Sci, Dept Pharmacol, Changsha 410008, Hunan, Peoples R China
[2] Penn State Univ, Coll Med, Penn State Hershey Canc Inst, Dept Pharmacol, Hershey, PA 17033 USA
[3] Milton S Hershey Med Ctr, Hershey, PA 17033 USA
基金
中国国家自然科学基金;
关键词
glycolysis cancer cells; cancer cells metabolism; Warburg effect; anticancer strategy; PYRUVATE-KINASE M2; INDUCIBLE FACTOR-I; GLUCOSE-6-PHOSPHATASE ACTIVITY; NUCLEAR TRANSLOCATION; AEROBIC GLYCOLYSIS; CANCER; GROWTH; MTOR; PKM2; EXPRESSION;
D O I
10.1038/aps.2016.47
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Tumor cells rely mainly on glycolysis for energy production even in the presence of sufficient oxygen, a phenomenon termed the Warburg effect, which is the most outstanding characteristic of energy metabolism in cancer cells. This metabolic adaptation is believed to be critical for tumor cell growth and proliferation, and a number of onco-proteins and tumor suppressors, including the PI3K/ Akt/ mTOR signaling pathway, Myc, hypoxia-inducible factor and p53, are involved in the regulation of this metabolic adaptation. Moreover, glycolytic cancer cells are often invasive and impervious to therapeutic intervention. Thus, altered energy metabolism is now appreciated as a hallmark of cancer and a promising target for cancer treatment. A better understanding of the biology and the regulatory mechanisms of aerobic glycolysis has the potential to facilitate the development of glycolysis-based therapeutic interventions for cancer. In addition, glycolysis inhibition combined with DNA damaging drugs or chemotherapeutic agents may be effective anticancer strategies through weakening cell damage repair capacity and enhancing drug cytotoxicity.
引用
收藏
页码:1013 / 1019
页数:7
相关论文
共 68 条
[1]   Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: Results from a multicenter prospective randomized trial [J].
Amadori, D ;
Frassineti, GL ;
De Matteis, A ;
Mustacchi, G ;
Santoro, A ;
Cariello, S ;
Ferrari, M ;
Nascimben, O ;
Nanni, O ;
Lombardi, A ;
Scarpi, E ;
Zoli, W .
BREAST CANCER RESEARCH AND TREATMENT, 1998, 49 (03) :209-217
[2]   Balancing biosynthesis and bioenergetics: metabolic programs in oncogenesis [J].
Barger, Jennifer F. ;
Plas, David R. .
ENDOCRINE-RELATED CANCER, 2010, 17 (04) :R287-R304
[3]   Stimulation of de Novo Pyrimidine Synthesis by Growth Signaling Through mTOR and S6K1 [J].
Ben-Sahra, Issam ;
Howell, Jessica J. ;
Asara, John M. ;
Manning, Brendan D. .
SCIENCE, 2013, 339 (6125) :1323-1328
[4]   New aspects of the Warburg effect in cancer cell biology [J].
Bensinger, Steven J. ;
Christofk, Heather R. .
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, 2012, 23 (04) :352-361
[5]   The reverse Warburg effect Glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts [J].
Bonuccelli, Gloria ;
Whitaker-Menezes, Diana ;
Castello-Cros, Remedios ;
Pavlides, Stephanos ;
Pestell, Richard G. ;
Fatatis, Alessandro ;
Witkiewicz, Agnieszka K. ;
Vander Heiden, Matthew G. ;
Migneco, Gemma ;
Chiavarina, Barbara ;
Frank, Philippe G. ;
Capozza, Franco ;
Flomenberg, Neal ;
Martinez-Outschoorn, Ubaldo E. ;
Sotgia, Federica ;
Lisanti, Michael P. .
CELL CYCLE, 2010, 9 (10) :1960-1971
[6]   Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival [J].
Casneuf, Veerle F. ;
Fonteyne, Philippe ;
Van Damme, Nancy ;
Demetter, Pieter ;
Pauwels, Patrick ;
de Hemptinne, Bernard ;
De Vos, Martine ;
Van de Wiele, Christophe ;
Peeters, Marc .
CANCER INVESTIGATION, 2008, 26 (08) :852-859
[7]   Halofuginone inhibits colorectal cancer growth through suppression of Akt/mTORC1 signaling and glucose metabolism [J].
Chen, Guo-Qing ;
Tang, Cheng-Fang ;
Shi, Xiao-Ke ;
Lin, Cheng-Yuan ;
Fatima, Sarwat ;
Pan, Xiao-Hua ;
Yang, Da-Jian ;
Zhang, Ge ;
Lu, Ai-Ping ;
Lin, Shu-Hai ;
Bian, Zhao-Xiang .
ONCOTARGET, 2015, 6 (27) :24148-24162
[8]  
Cheng Y, 2016, ONCOGENE, DOI [10.1038/onc.2016.166, DOI 10.1038/0NC.2016.166]
[9]   The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth [J].
Christofk, Heather R. ;
Vander Heiden, Matthew G. ;
Harris, Marian H. ;
Ramanathan, Arvind ;
Gerszten, Robert E. ;
Wei, Ru ;
Fleming, Mark D. ;
Schreiber, Stuart L. ;
Cantley, Lewis C. .
NATURE, 2008, 452 (7184) :230-U74
[10]   Pyruvate kinase M2 is a phosphotyrosine-binding protein [J].
Christofk, Heather R. ;
Vander Heiden, Matthew G. ;
Wu, Ning ;
Asara, John M. ;
Cantley, Lewis C. .
NATURE, 2008, 452 (7184) :181-U27